Cargando…

SAMe-TT(2)R(2) Score in the Outpatient Anticoagulation Clinic to Predict Time in Therapeutic Range and Adverse Events

BACKGROUND: The SAMe-TT(2)R(2) score was developed to predict which patients on oral anticoagulation with vitamin K antagonists (VKAs) will reach an adequate time in therapeutic range (TTR) (> 65%-70%). Studies have reported a relationship between this score and the occurrence of adverse events....

Descripción completa

Detalles Bibliográficos
Autores principales: Pivatto Júnior, Fernando, Scheffel, Rafael Selbach, Ries, Lucas, Wolkind, Ricardo Roitman, Marobin, Roberta, Barkan, Sabrina Sigal, Amon, Luís Carlos, Biolo, Andréia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sociedade Brasileira de Cardiologia - SBC 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5421467/
https://www.ncbi.nlm.nih.gov/pubmed/28538758
http://dx.doi.org/10.5935/abc.20170052
Descripción
Sumario:BACKGROUND: The SAMe-TT(2)R(2) score was developed to predict which patients on oral anticoagulation with vitamin K antagonists (VKAs) will reach an adequate time in therapeutic range (TTR) (> 65%-70%). Studies have reported a relationship between this score and the occurrence of adverse events. OBJECTIVE: To describe the TTR according to the score, in addition to relating the score obtained with the occurrence of adverse events in patients with nonvalvular atrial fibrillation (AF) on oral anticoagulation with VKAs. METHODS: Retrospective cohort study including patients with nonvalvular AF attending an outpatient anticoagulation clinic of a tertiary hospital. Visits to the outpatient clinic and emergency, as well as hospital admissions to the institution, during 2014 were evaluated. The TTR was calculated through the Rosendaal´s method. RESULTS: We analyzed 263 patients (median TTR, 62.5%). The low-risk group (score 0-1) had a better median TTR as compared with the high-risk group (score ≥ 2): 69.2% vs. 56.3%, p = 0.002. Similarly, the percentage of patients with TTR ≥ 60%, 65% or 70% was higher in the low-risk group (p < 0.001, p = 0.001 and p = 0.003, respectively). The high-risk group had a higher percentage of adverse events (11.2% vs. 7.2%), although not significant (p = 0.369). CONCLUSIONS: The SAMe-TT(2)R(2) score proved to be effective to predict patients with a better TTR, but was not associated with adverse events.